• ADMA Biologics President, CEO and director Adam S. Grossman sold 147,000 common shares at $12 on November 5, 2026.
• Grossman also exercised stock options for 105,000 common shares at $5.4 per share.
• Following the transactions, he directly held 2,070,777 common shares and indirectly held 1,724,383 common shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADMA Biologics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-042166), on November 05, 2026, and is solely responsible for the information contained therein.